Report Sections

See All Reports

  • HP:0000726: Dementia
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0000726: Dementia

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (21)


    Name (Synonyms) Correlation
    drug3495 SPIRIT-remote Wiki 0.35
    drug4518 hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint Wiki 0.35
    drug3494 SPIRIT-in person Wiki 0.35
    Name (Synonyms) Correlation
    drug1743 Home Health Agency Care Wiki 0.35
    drug4538 intravenous immunoglobulin therapy Wiki 0.35
    drug4536 intermittent theta burst stimulation (iTBS) Wiki 0.35
    drug299 Anthocyanins Wiki 0.35
    drug4760 supportive and symptomatic treatment Wiki 0.35
    drug4523 imaging, blood tests Wiki 0.35
    drug957 Cognitive Stimulation Wiki 0.35
    drug4528 inhalable hydroxychloroquine (HCQ) Wiki 0.35
    drug681 CAPABLE Transitions Wiki 0.35
    drug1203 Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta Wiki 0.35
    drug2086 LIVE Wiki 0.35
    drug2814 Paramedic Coaching Wiki 0.35
    drug3934 Telephone interview Wiki 0.35
    drug1201 DiaNose Wiki 0.35
    drug732 COVID WHELD Wiki 0.35
    drug4172 Usual care Wiki 0.18
    drug1193 Dexamethasone Wiki 0.12
    drug2916 Placebo Wiki 0.02

    Correlated MeSH Terms (5)


    Name (Synonyms) Correlation
    D003704 Dementia NIH 1.00
    D060825 Cognitive Dysfunction NIH 0.27
    D019965 Neurocognitive Disorders NIH 0.25
    Name (Synonyms) Correlation
    D003324 Coronary Artery Disease NIH 0.12
    D007249 Inflammation NIH 0.06

    Correlated HPO Terms (2)


    Name (Synonyms) Correlation
    HP:0001268 Mental deterioration HPO 0.27
    HP:0001677 Coronary artery atherosclerosis HPO 0.12

    Clinical Trials

    Navigate: Correlations   HPO

    There are 8 clinical trials


    1 Preparation for End-of-Life Decision Making in Mild Dementia

    The proposed study will adapt and pilot test an efficacious advance care planning interventions, SPIRIT (Sharing Patient's Illness Representations to Increase Trust), with patients with mild dementia and their surrogates to promote open, honest discussions while such discussions about end-of-life care are possible. The study includes two phases: Phase I to adapt, pretest, and refine SPIRIT, and Phase II to pilot test the refined SPIRIT to formally evaluate its feasibility, acceptability, and preliminary efficacy. The final products will be the modified SPIRIT intervention that improves dementia patient and surrogate outcomes, and standardized intervention manuals, including the SPIRIT Interview Guide, fidelity assessment, and training materials. Patient and surrogate decision maker dyads will participate in a single SPIRIT session and will then have a follow up phone call 2-3 days later. One year after the SPIRIT session some surrogates will be contacted to provide additional feedback about the intervention.

    NCT03311711
    Conditions
    1. Dementia
    Interventions
    1. Behavioral: SPIRIT-in person
    2. Behavioral: SPIRIT-remote
    3. Behavioral: Usual care
    MeSH:Dementia
    HPO:Dementia

    Primary Outcomes

    Description: Dyad congruence will be assessed using the Goals-of-Care Tool which has been modified to include two scenarios relevant to the context of dementia. There are three response options: "The goals of care should focus on delaying my death no matter what, and thus I want to continue life-sustaining treatment", "The goals of care should focus on my comfort and peace, and thus I do not want life-sustaining treatment", and "I am not sure". Patients and surrogates complete this tool independently and their responses are then compared to determine dyad congruence (either congruent in both scenarios or incongruent). If both members of the dyad endorse "I am not sure", they are considered incongruent.

    Measure: Change in dyad congruence among Phase II participants

    Time: Baseline, follow up phone call (2-3 days post-intervention)

    Description: Surrogate decision-making confidence will be measured using the 5-item Decision Making Confidence (DMC) scale. DMC assesses a surrogate's confidence in knowing the patient's wishes, ability to make treatment decisions even in a highly stressful situation, ability to seek information about risks and benefits of medical choices, ability to handle unwanted pressure from others, and ability to communicate with providers about the patient's wishes. Surrogates indicate how confident they are about making medical decisions, if the patient becomes unable to make their own decisions, by their level of agreement with statements along a scale of (0) "not confident at all" to (4) "Very confident". Total scores range from 0 - 20, with higher scores indicating greater confidence.

    Measure: Change in Surrogate's Decision Making Confidence (DMC) scale score among Phase II participants

    Time: Baseline, follow up phone call (2-3 days post-intervention)

    Description: The Overall Preparedness Scale for end-of-life decision making for surrogates is a 21-item investigator-developed measure. The measure assesses the level of preparedness for end-of-life decision making in the cognitive, emotional, and behavioral dimensions on a 4-point scale (1=strongly disagree to 4=strongly agree). Total scores range from 21 to 84, with higher scores indicating higher levels of preparedness.

    Measure: Change in Surrogate's Overall Preparedness Scale

    Time: Baseline, follow up phone call (2-3 days post-intervention)

    Secondary Outcomes

    Description: Medical records will be reviewed to determine if the patient completed an advance directive (a medical power of attorney or living will) by 12 months post-intervention. If there is no documentation, the surrogate will be contacted to get confirmation on the status of the Advance Directive.

    Measure: Completion of Advance Directives among Phase I participants

    Time: 12 months post-intervention

    Description: Medical records will be reviewed to determine if the patient completed an advance directive (a medical power of attorney or living will) by 12 months post-intervention. If there is no documentation, the surrogate will be contacted to get confirmation on the status of the Advance Directive.

    Measure: Completion of Advance Directives among Phase II participants

    Time: 12 months post-intervention

    Description: The Overall Preparedness Scale for end-of-life decision making for patients is a 20-item investigator-developed measure. The measure assesses the level of preparedness for end-of-life decision making in the cognitive, emotional, and behavioral dimensions on a 4-point scale (1=strongly disagree to 4=strongly agree). Total scores range from 20 to 80, with higher scores indicating higher levels of preparedness.

    Measure: Change in Patient's Overall Preparedness Scale

    Time: Baseline, follow up phone call (2-3 days post-intervention)
    2 A Randomized, 24-week Parallel-group Placebo-controlled Multicenter (Phase 2) Study of Anthocyanins in People at Risk for Dementia

    The aim of this project is to study the safety and efficacy of anthocyanins in improving key dementia-related mechanisms and cognitive functioning in older people at risk for dementia. Secondary analyses will include a variety of biological measures, including biochemistry, imaging and cardiovascular measures.

    NCT03419039
    Conditions
    1. Dementia
    2. Inflammation
    3. Mild Cognitive Impairment
    4. Coronary Artery Disease
    Interventions
    1. Dietary Supplement: Anthocyanins
    2. Dietary Supplement: Placebo
    MeSH:Dementia Coronary Artery Disease Inflammation Cognitive Dysfunction
    HPO:Cognitive impairment Coronary artery atherosclerosis Dementia Mental deterioration

    Primary Outcomes

    Description: A composite measure from the CogTrack battery

    Measure: Quality of episodic memory.

    Time: Baseline to 24 weeks

    Secondary Outcomes

    Description: CogTrack evaluates attentional intensity index, sustained intensity index, cognitive reaction time, attentional fluctuation index, quality of working memory, quality of episodic memory and speed of memory retrieval.

    Measure: Secondary endpoints from CogTrack

    Time: Baseline to 24 weeks

    Description: Lipid profile, fatty acids, cytokines ( among others: IL-1, IL-2, IL-6, TNF-a), plasma antoxidant status and vitamins (lipid peroxidation markers, vitamins E, C, A, total plasma antioxidant capacity, glutathion)., carinthine, blood glucose, HbA1c, anthocyanins and metabolites, mapping of a-beta degradation products.

    Measure: Blood outcome analysis

    Time: Baseline to 24 weeks

    Description: Flow-mediated dilation (FMD), Cardiac-ankle vascular index (CAVI), photoplethysmogram (PPG).

    Measure: Cardiovascular parameters

    Time: Baseline to 24 weeks

    Description: Microbiota

    Measure: Fecal analysis

    Time: Baseline to 24 weeks

    Description: kyrinin

    Measure: Urine analysis

    Time: Baseline to 24 weeks

    Description: anthocyanin metabolites

    Measure: CSF measurements

    Time: Baseline to 24 weeks

    Description: Diagnosing and follow-up of cerebrovascular disease

    Measure: MR-imaging/CT

    Time: Baseline to 24 weeks
    3 LIVE@Home.Path: a Mixed Method, Stepped Wedge and Randomized Controlled Trial Innovating the Clinical Pathway for Home-dwelling Persons With Dementia and Their Families

    This study aims at developing, implementing and evaluating a complex intervention involving Learning, Innovation, Volunteers and Empowerment for home dwelling persons with dementia and their caregivers. The investigators hypothesise that a successfully implemented intervention will reduce caregivers burden and be cost-effective.

    NCT04043364
    Conditions
    1. Dementia
    2. Home-dwelling
    3. Caregiver
    Interventions
    1. Behavioral: LIVE
    MeSH:Dementia
    HPO:Dementia

    Primary Outcomes

    Description: RUD:A validated tool for assessment of time use for cost effectiveness analyses, measuring total time use in hours/day for different activities, numbers of contact points with care professionals and use of medications, high time use, many contacts and many medications indicates high resource use

    Measure: Resource Utilization in Dementia

    Time: up to 24 months follow up, assesment every 6 months

    Description: RSS: measuring caregiver distress, 15 items ranging from 0-4, high score indicates high burden

    Measure: Relative stress scale

    Time: up to 24 months follow up, assessment every 6 months

    Secondary Outcomes

    Description: I-ADL scale assessing instrumental activities such as use of telephone, economy, household, public transport and shopping, range from 8-31, higher score indicates poorer functioning

    Measure: Activities of daily living, instrumental

    Time: 24 months follow up, assesment every 6 months

    Description: CSDD: Cornell scale for depression in dementia, range 0-38, high score indicates high symptom load

    Measure: Depression and mood

    Time: 24 months follow up, assesment every 6 months

    Description: CMAI: Cohen-Mansfield Agitation Inventory, 29 items assessing the frequency of agitated behaviour, range 29-203, high score indicates higher severity

    Measure: Agitation

    Time: 24 months follow up, assesment every 6 months

    Description: NPI: presence, severity and burden of depression, anxiety, psychosis and motor disturbances, range from 0-144, high score indicates frequent, severe and burdensome symptoms

    Measure: Neuropsychiatric symptoms

    Time: 24 months follow up, assesment every 6 months

    Description: Falls, disappearances outdoor, admissions to acute wards, fire hazard

    Measure: Adverse events

    Time: 24 months follow up, assesment every 6 months

    Description: number of technical aids, cognitive intervention devices and assisted-living systems

    Measure: Use of assistive technology

    Time: 24 months follow up, assesment every 6 months

    Description: number of participants with contact with a volunteer, number of hours spent with volunteer

    Measure: Use of volunteers

    Time: 24 months follow up, assesment every 6 months

    Description: P-ADL, assessing personal activities such as toileting, grooming, dressing, transfer and eating, scale range 6-30, higher score indicates poorer personal functioning

    Measure: Activities of daily living, personal

    Time: 24 months follow up, assesment every 6 months

    Description: EQ-5D-5L, Descriptive measure of health related quality of life comprising 5 Dimensions With 5 Levels each, scores can be converted to a single summary index number

    Measure: Quality of Life

    Time: 24 months follow up, assesment every 6 months

    Description: EQ-5D, Descriptive measure of quality of life rated on a VAS scale range 0-100, high score indicates good health

    Measure: Quality of Life VAS scale

    Time: 24 months follow up, assesment every 6 months

    Description: QoL-AD: Quality of life in Alzheimer dementia, 13 items likert scale, range from 13-52 points, high score indicates high quality of life

    Measure: Quality of Life

    Time: 24 months follow up, assesment every 6 months

    Description: number of hours spent with a volunteer

    Measure: Use of volunteers

    Time: 24 months follow up, assesment every 6 months

    Description: Clinical global impression of change, to quantify and track patient progress and treatment response on a scale from 1 to 7, at which 7 indicates substantial worsening.

    Measure: Change achieving

    Time: at the start of intervention, and every 6 months

    Description: GDS: Geriatric depression scale, 30 items rated yeas or no, high score indicates high burden

    Measure: Caregiver depression

    Time: 24 months follow up, assesment every 6 months

    Description: GMHR: General medical health rating scale, 4 point likert scale, range from 1-4, high score indicates high comorbidity burden

    Measure: Comorbidity

    Time: 24 months follow up, assesment every 6 months

    Description: MOBID-2: assesses the intensity of pain based on interpretation of pain related behaviour, range from 0-10, high score indicates high pain intensity

    Measure: Pain in dementia

    Time: 24 months follow up, assesment every 6 months

    Description: IQ CODE: Proxy rater instrument for assessment of change in cognitive performance the last 10 years, range 16-80, high score indicates great decline

    Measure: Change in cognitive performance

    Time: Baseline

    Description: Self and proxy reported use of medications, both regular and on demand

    Measure: Medication use

    Time: At the start of the intervention, and every 6 onth follow up

    Description: Participation in educational programes, both for persons with dementia and for caregivers.

    Measure: Participation in educational programs

    Time: 24 months follow up, assessment every 6 months

    Other Outcomes

    Description: Caregivers perception of risk of contamination With Sars-Cov-10

    Measure: COVID-19: risk perception

    Time: month 6 to month 12 (during COVID-19 lock down in Norway)

    Description: Change in services and contact due to restrictions of COVID-19

    Measure: COVID-19: restrictions

    Time: month 6 to month 12 (during COVID-19 lock down in Norway)

    Description: Caregivers perception of caregiver burden during COVID-19

    Measure: COVID-19: caregiver burden

    Time: month 6 to month 12 (during COVID-19 lock down in Norway)

    Description: NPI: change in presence, severity and burden of depression, anxiety, psychosis and motor disturbances

    Measure: COVID-19: neuropsychiatric symptoms

    Time: month 6 to month 12 (during COVID-19 lock down in Norway)

    Description: CSDD: Change in cornell scale for depression in dementia.

    Measure: COVID-19: depression and mood

    Time: month 6 to month 12 (during COVID-19 lock down in Norway)
    4 Community Paramedic Coaching Program for Caregivers and People With Dementia (CP3D)

    This pilot study is designed to evaluate the potential effectiveness of the implementation strategy and intervention delivery model of a community paramedic coaching program for caregivers of persons with dementia, in direct coordination with the participant and caregiver's primary health care team. Specifically, the acceptability, appropriateness, and feasibility of the program will be assessed, collecting data from all implementation stakeholders at baseline, 13 weeks, 25 weeks, and post-intervention (~50 weeks) using quantitative survey instruments and qualitative interviews.

    NCT04239924
    Conditions
    1. Dementia
    Interventions
    1. Behavioral: Paramedic Coaching
    MeSH:Dementia
    HPO:Dementia

    Primary Outcomes

    Description: As determined by abstracting the medical records, the investigators are testing the hypothesis that the number of visits to the Emergency Department is lower than commonly reported in the literature for persons with dementia.

    Measure: Number of Visits to the Emergency Department by the Person with Dementia

    Time: up to 24 months

    Description: As determined by abstracting the medical records, the investigators are testing the hypothesis that the number of visits to the Emergency Department is lower than commonly reported in the literature for average older adults.

    Measure: Number of Visits to the Emergency Department by the Caregiver of the Person with Dementia

    Time: up to 24 months

    Description: The intervention will be deemed feasible if at least 75% of the intended coaching phone calls are completed. The minimum number of coaching calls is 3, additional calls will be scheduled opposite weeks of home visits as needed.

    Measure: Feasibility: Proportion of Coaching Phone Calls Completed

    Time: up to 12 months

    Description: The intervention will be deemed feasible if at least 75% of the intended home visits are completed. The minimum number of intended home visits is 9.

    Measure: Feasibility: Proportion of Coaching Home Visits Completed

    Time: up to 12 months

    Secondary Outcomes

    Description: The Zarit Burden Interview measures caregiver burden. This is a 12-item survey with a total possible range of scores from 0-48, where higher scores indicate increased burden. The investigators hypothesize the score will decrease as a result of the intervention.

    Measure: Change in Zarit Burden Interview (ZBI-12) Score

    Time: First home visit (~ week 1), week 13, week 25, and last home visit (~up to week 50)

    Description: The GAD-7 is a 7-item survey that measures anxiety symptom severity. The total possible range of scores is 0-21, where higher scores indicate increased symptom severity. The investigators hypothesize the score will decrease as a result of the intervention.

    Measure: Change in Generalized Anxiety Disorder (GAD-7) Score

    Time: Baseline, week 13, week 25, week 50

    Description: The CESD-10 is a general measure of depression frequently used in caregiver studies. It is a 10-item survey with a total possible range of scores of 0-30 where higher scores indicate increased depression. The investigators hypothesize the score will decrease as a result of the intervention.

    Measure: Change in Center for Epidemiologic Studies Depression Scale (CESD-10)

    Time: First home visit (~ week 1), week 13, week 25, and last home visit (~up to week 50)

    Description: The RCSS is a 6-item survey used to measure the positive aspects of caring. The range of total possible scores is 6-30 where higher scores indicate increased caregiver satisfaction. The investigators hypothesize the score will increase as a result of the intervention.

    Measure: Change in Revised Caregiving Satisfaction Scale (RCSS)

    Time: Baseline, week 13, week 25, week 50

    Description: The revised scale for caregiving self-efficacy measures three domains: obtaining respite, responding to disruptive patient behaviors, and controlling upsetting thoughts. It is a 15-item scale with a total possible range of scores between 0-100, where higher scores are better. The investigators hypothesize the score will increase as a result of the intervention.

    Measure: Change in Revised Scale for Caregiving Self-Efficacy

    Time: First home visit (~ week 1) and last home visit (~up to week 50)

    Description: WFC is measured for the caregiver. It is a 6-item survey with a total possible range of scores between 6-30 with higher scores indicating lesser work-family conflict. The investigators hypothesize the score will increase as a result of the intervention.

    Measure: Change in Work-Family Conflict Scale (WFC)

    Time: First home visit (~ week 1) and last home visit (~up to week 50)

    Description: C-DEMQOL is measured for the caregiver. The investigators will be asking 18 of the questions from the scale to understand the quality of life the caregivers experience. Scores can range from 18-90, with a higher score reflecting a higher quality of life.

    Measure: Change in Caregiver Quality of Life (C-DEMQOL) Score

    Time: Baseline and 62 weeks (12 weeks post completion)

    Description: DKAS is measured for the caregiver. It is a 25 item true-false survey of facts about dementia. Scoring is by measuring the proportion of questions answered correctly.

    Measure: Change in Knowledge of Dementia (DKAS) Score

    Time: Baseline and 62 weeks (12 weeks post completion)

    Description: As determined by abstracting the medical records, the investigators are characterizing the number of contacts with outpatient clinics for persons with dementia.

    Measure: Clinic Utilization by Persons with Dementia

    Time: up to 24 months

    Description: As determined by abstracting the medical records, the investigators are characterizing the number of contacts with outpatient clinics for caregivers of persons with dementia.

    Measure: Clinic Utilization by Caregivers of Persons with Dementia

    Time: up to 24 months

    Description: Assesses caregivers perception of communication with health care team and extent to which the team considers their capacity and preferences in decision making. This measure consists of 12 questions, with scores ranging from 12-60, where higher scores indicate increased communication with the health care team.

    Measure: Change in Caregiver Perceptions About Communication With Clinical Team Members (CAPACITY) Measure

    Time: Baseline and 62 weeks (12 weeks post completion)
    5 Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia

    Coronavirus disease 2019 has forced worldwide the implementation of unprecedented restrictions to control its rapid spread and mitigate its impact. The Spanish government has enforced social distancing, quarantine and home confinement. This restriction of daily life activities and separation from loved ones may lead to social isolation and loneliness with health-related consequences in community-dwelling older adults with mild cognitive impairment or mild dementia and their caregivers. Additionally, an inadequate access to healthcare and social support services may aggravate chronic conditions. Technology home-based interventions emerge for combating social isolation and loneliness preventing the risk of viral exposure. The aim of this multicentre cohort study is to explore, analyze and determine the impact of social isolation on: 1) cognition, quality of life, mood, technophilia and perceived stress of community-dwelling older adults with mild cognitive impairment or mild dementia, and on caregiver burden; 2) health and social care services access and utilization, and 3) cognitive, social and entertainment use of ICTs. This study will be conducted in two Spanish regions Andalucía (Málaga) and Cataluña (Tarrasa). In total 414 dyads, consisting of a person with mild cognitive impairment or mild dementia (PMCI/MD) and their informal caregiver will be contacted by telephone. Potential respondents will be participants of the SMART 4 MD (N=2921), TV-AssistDem (N=100) and INFINITy (N=23) clinical trials. The change in means in the variables will be analyzed comparing baseline results in the previous studies with those during and after confinement using the ANOVA test of repeated measures or the non-parametric Friedman test if appropriate. The performance of a multivariate analysis of variance (ANCOVA) to introduce possible covariates will also be contemplated. A 95% confidence level will be used.

    NCT04385797
    Conditions
    1. Mild Cognitive Impairment
    2. Dementia
    Interventions
    1. Other: Telephone interview
    MeSH:Dementia Cognitive Dysfunction
    HPO:Cognitive impairment Dementia Mental deterioration

    Primary Outcomes

    Description: The Mini-Mental State Examination (MMSE) (23) will be used to assess the cognitive function of the PMCI/MD. The most common cutoff scores for cognitive impairment and dementia are ranging 23 to 27 over 30. As telephone call interviewing will be the safest means to communicate with the PMCI/MD during and after the COVID-19 pandemic the 22 items telephone version of the MMSE will be used (24). All points of the MMSE can be covered in the telephone version except the last section assessing language and motor skills. In the phone version, we will ask the subject to repeat a phrase and name one item (For example: "Tell me, what is the name of the object you are using to talk to me?"). However, a second item will be not be named, nor will be the person be asked to follow a three-stage command, read and obey a sentence, write a sentence, or copy an intersecting pentagon as in the original version.

    Measure: Change on cognitive function in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Secondary Outcomes

    Description: The Quality of Life-Alzheimer's Disease Scale (QoL-AD) (19-22) is an instrument specifically designed to measure QoL in PMCI/MD from the perspective of both the patient and the informal caregiver. It is a 13-item measure, which includes assessments of the person´s relationships with friends and family, financial situation, physical condition, mood, memory, and an overall assessment of life quality. Response are 4-point multiple choice options (1 = poor, 2= fair, 3= good, 4 = excellent). Scale scores range from 13 to 52, with higher scores indicating greater quality of life. When cognitive function may be compromised, informal caregivers will complete the QoL-AD, on behalf of the PMCI/MD.

    Measure: Change on quality of life in Alzheimer´s Disease in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The European Quality of Life 5 Dimensions 3 Levels (EuroQoL-5D-3L) is a standardized generic instrument consisting of a descriptive system and a visual analogue scale (VAS). The descriptive system comprises 5 dimensions covering mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, moderate problems and extreme problems. A 1-digit number expresses the level selected for that dimension. The digits can be combined into a 5-digit number that describes the patient's health state. The VAS records the patient's self-rated health on a vertical scale, where the endpoints are 100 = 'The best health you can imagine' and 0 = 'The worst health you can imagine'. EuroQoL-5D-3L has been shown to correlate well with QoL-AD, indicating that using both measures side-by-side is compatible.

    Measure: Change on quality of life in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Short Form of the Geriatric Depression Scale (GDS) (25) will be used to assess mood. Of the 15 items, 10 indicate depression when answered positively, while the rest (1, 5, 7, 11, 13) when answered negatively. Scores of 0-4 are considered normal, 5-8 indicate mild depression, 9-11 moderate depression, and 12-15 severe depression.

    Measure: Change on mood in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Instrument for Measuring Older People's Attitudes Toward Technology (TechPH) measures older people's attitudes and enthusiasm for health technology (26). This instrument refers to technophilia as a person's enthusiasm for and positive feelings toward their technology use and absence of the fears and doubts some older people could have about their ability to manage using new technology. The six items of the instrument measure two factors of technophilia: 3 items concerning techEnthusiasm and 3 items techAnxiety. Response are constructed with a five-point Likert scale questionnaire, ranging from 1 (fully disagree) to 5 (fully agree).

    Measure: Change on technophilia in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Perceived Stress Scale (PSS) measures the degree to which situations in one's life are appraised as stressful. The scale has 10 questions regarding feelings and thoughts during the last month and are rated according to frecuency 0 = Never 1 = Almost Never 2 = Sometimes 3 = Fairly Often 4 = Very Often. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the four positively stated items (items 4, 5, 7, & 8) and then summing across all scale items

    Measure: Change on perceived stress in people with mild cognitive impairment or mild dementia during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Zarit Burden Interview (ZBI-12) is a 12-item scale with each answer chosen from a 5-point Likert scale (Nearly always=4, Quite frequently=3, Sometimes=2, Rarely=1, Never=0). It is a shortened version of the original scale, was developed specifically for informal caregivers of PMCI/MD and covers issues such as caregiver stress and the degree to which caring is affecting their health and social life. Total score range 0 to 48 (0-10= no to mild burden, 10-20= mild to moderate burden >20= high burden).

    Measure: Change on caregiver burden prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Client Service Receipt Inventory (CSRI) (32,33) scale will be used to evaluate the service utilization. This scale is an internationally used method for gathering data on service utilization and other domains relevant for economic analysis of mental health care. It has five sections: background client information, accommodation and living situation, employment history, earnings and benefits, a record of services usually used and information about informal caregiver support. The sections assessed will be consultations, admissions and visits, grouped into subsections according to hospital, specialist, primary or home care. Treatment related to hospital admissions or illness exacerbation will also be assessed. It´s adaptability ensures it is compatible with the research aims, context, participants' likely circumstances, and the quantity and precision of information required.

    Measure: Change on healthcare and social support services access prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: Use of ICTs (SmartPhone, Tablet, Computer, Smart-TV, or other) to contact healthcare and social support services, to stimulate cognition, to facilitate social connectedness (telephone call, video call, texting...), to access COVID-19 information and to enable entertainment.

    Measure: Change from health, cognitive, social, informative and entertainment related uses of ICT during and after confinement.

    Time: Through study completion, an average of 6 months
    6 Care at 360º: A Long-term Individual Cognitive Stimulation Program for Older Adults With Neurocognitive Disorders, Non-Institutionalized and Socially Vulnerable

    The aim of the intervention proposed in the present study is to assess the effect of a cognitive stimulation (CS) intervention program in an individual and long-term format, for non-institutionalized elderly people with neurocognitive disorders and in a situation of social vulnerability. Specifically, to test the effectiveness of CS on the global cognitive state, on mood state, on quality of life and on functional state. The program will be composed by 50 sessions, including three of assessment sessions (pre, intra and post-intervention). Each session will have a duration of 45 minutes with a weekly frequency. Control group participants will maintain their treatment as usual.

    NCT04417751
    Conditions
    1. Neurocognitive Disorders
    2. Dementia
    3. Cognitive Impairment
    4. Cognitive Decline
    5. Cognitive Dysfunction
    6. Social Behavior
    Interventions
    1. Behavioral: Cognitive Stimulation
    MeSH:Dementia Cognitive Dysfunction Neurocognitive Disorders
    HPO:Cognitive impairment Dementia Mental deterioration

    Primary Outcomes

    Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Mini-Mental State Examination is a brief screening test for cognitive function. Assesses 6 cognitive functions: orientation, registration, attention and calculation, recall, language and visuoconstructive ability. Global score ranges from 0-30 points, higher scores indicate better cognitive function.

    Measure: Cognitive state evaluated through Mini-Mental State Examination

    Time: Pre-intervention

    Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Mini-Mental State Examination is a brief screening test for cognitive function. Assesses 6 cognitive functions: orientation, registration, attention and calculation, recall, language and visuoconstructive ability. Global score ranges from 0-30 points, higher scores indicate better cognitive function.

    Measure: Change in cognitive state evaluated through Mini-Mental State Examination

    Time: 6 months after the beginning of the intervention

    Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Mini-Mental State Examination is a brief screening test for cognitive function. Assesses 6 cognitive functions: orientation, registration, attention and calculation, recall, language and visuoconstructive ability. Global score ranges from 0-30 points, higher scores indicate better cognitive function.

    Measure: Change in cognitive state evaluated through Mini-Mental State Examination

    Time: 12 months after the beginning of the intervention

    Description: It's a 32-item mild cognitive impairment screening instrument that assesses eight cognitive functions: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall and orientation. Montreal Cognitive Assessment score is calculated by adding the points of the tasks successfully completed, and it ranges from 0 to 30 points, being that higher scores indicate better cognitive performance.

    Measure: Cognitive performance evaluated through Montreal Cognitive Assessment

    Time: Pre-intervention

    Description: It's a 32-item mild cognitive impairment screening instrument that assesses eight cognitive functions: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall and orientation. Montreal Cognitive Assessment score is calculated by adding the points of the tasks successfully completed, and it ranges from 0 to 30 points, being that higher scores indicate better cognitive performance.

    Measure: Change in cognitive performance evaluated through Montreal Cognitive Assessment

    Time: 6 months after the beginning of the intervention

    Description: It's a 32-item mild cognitive impairment screening instrument that assesses eight cognitive functions: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall and orientation. Montreal Cognitive Assessment score is calculated by adding the points of the tasks successfully completed, and it ranges from 0 to 30 points, being that higher scores indicate better cognitive performance.

    Measure: Change in cognitive performance evaluated through Montreal Cognitive Assessment

    Time: 12 months after the beginning of the intervention

    Secondary Outcomes

    Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Geriatric Depression Scale -15 is a screening test for depressive symptoms in elderly adults. Assesses depression in the elderly by distinguishing between depressive and dementia symptoms. This instrument does not include somatic conditions common to the elderly, such as appetite, sleep or sexual disturbances, or lower energy level. The overall score ranges from 0 to 15. The higher the score, the greater the severity of the depressive symptoms.

    Measure: Depressive symptoms evaluated through Geriatric Depression Scale -15

    Time: Pre intervention

    Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Geriatric Depression Scale -15 is a screening test for depressive symptoms in elderly adults. Assesses depression in the elderly by distinguishing between depressive and dementia symptoms. This instrument does not include somatic conditions common to the elderly, such as appetite, sleep or sexual disturbances, or lower energy level. The overall score ranges from 0 to 15. The higher the score, the greater the severity of the depressive symptoms.

    Measure: Change in depressive symptoms evaluated through Geriatric Depression Scale -15

    Time: 6 months after the beginning of the intervention

    Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Geriatric Depression Scale -15 is a screening test for depressive symptoms in elderly adults. Assesses depression in the elderly by distinguishing between depressive and dementia symptoms. This instrument does not include somatic conditions common to the elderly, such as appetite, sleep or sexual disturbances, or lower energy level. The overall score ranges from 0 to 15. The higher the score, the greater the severity of the depressive symptoms.

    Measure: Change in depressive symptoms evaluated through Geriatric Depression Scale -15

    Time: 12 months after the beginning of the intervention

    Description: Significant statistic improvement in the participant's test scores between pre-intervention assessment and postintervention assessment. Quality of Life - Alzheimer's Disease is an instrument to assess quality of life in people diagnosed with dementia, gathering information from the patient and the caregiver. It is composed by 13 items regarding perception of health, mood, functional abilities, interpersonal relationships and hobbies, decision making ability and life in general. It has good psychometric characteristics and it's use has been recommended to evaluate psychosocial interventions. Scores range between 13 - 52 points. Higher scores indicate better quality of life.

    Measure: Quality of life evaluated through Quality of Life - Alzheimer's Disease: score

    Time: Pre-intervention

    Description: Significant statistic improvement in the participant's test scores between pre-intervention assessment and postintervention assessment. Quality of Life - Alzheimer's Disease is an instrument to assess quality of life in people diagnosed with dementia, gathering information from the patient and the caregiver. It is composed by 13 items regarding perception of health, mood, functional abilities, interpersonal relationships and hobbies, decision making ability and life in general. It has good psychometric characteristics and it's use has been recommended to evaluate psychosocial interventions. Scores range between 13 - 52 points. Higher scores indicate better quality of life.

    Measure: Change in quality of life evaluated through Quality of Life - Alzheimer's Disease: score

    Time: 6 months after the beginning of the intervention

    Description: Significant statistic improvement in the participant's test scores between pre-intervention assessment and postintervention assessment. Quality of Life - Alzheimer's Disease is an instrument to assess quality of life in people diagnosed with dementia, gathering information from the patient and the caregiver. It is composed by 13 items regarding perception of health, mood, functional abilities, interpersonal relationships and hobbies, decision making ability and life in general. It has good psychometric characteristics and it's use has been recommended to evaluate psychosocial interventions. Scores range between 13 - 52 points. Higher scores indicate better quality of life.

    Measure: Change in quality of life evaluated through Quality of Life - Alzheimer's Disease: score

    Time: 12 months after the beginning of the intervention

    Description: It's an instrument that assesses the independence level of the elderly people regarding IADL's. A score is assigned according to the person's ability to perform a given task. A set of three, four or five options is suggested for each question, which is scored from 1 to 3, 1 to 4 or 1 to 5 points. The highest score corresponds to a greater degree of dependency. If a task does not apply because the person did not perform it in the pre-morbid period, the score for that task is not included in the total score, that is, the maximum possible score includes only the maximum scores of the tasks that the person performed. The score ranges from 8 to 30 points (a score of 8 points means that th person is independent; between 9 and 20 points means a moderate dependency; greater than 20 points means severe dependency).

    Measure: Functional status is assessed using the Lawton and Brody Instrumental Activities of Daily Living.

    Time: Pre-intervention

    Description: It's an instrument that assesses the independence level of the elderly people regarding IADL's. A score is assigned according to the person's ability to perform a given task. A set of three, four or five options is suggested for each question, which is scored from 1 to 3, 1 to 4 or 1 to 5 points. The highest score corresponds to a greater degree of dependency. If a task does not apply because the person did not perform it in the pre-morbid period, the score for that task is not included in the total score, that is, the maximum possible score includes only the maximum scores of the tasks that the person performed. The score ranges from 8 to 30 points (a score of 8 points means that th person is independent; between 9 and 20 points means a moderate dependency; greater than 20 points means severe dependency).

    Measure: Change in functional status is assessed using the Lawton and Brody Instrumental Activities of Daily Living.

    Time: 6 months after the beginning of the intervention

    Description: It's an instrument that assesses the independence level of the elderly people regarding IADL's. A score is assigned according to the person's ability to perform a given task. A set of three, four or five options is suggested for each question, which is scored from 1 to 3, 1 to 4 or 1 to 5 points. The highest score corresponds to a greater degree of dependency. If a task does not apply because the person did not perform it in the pre-morbid period, the score for that task is not included in the total score, that is, the maximum possible score includes only the maximum scores of the tasks that the person performed. The score ranges from 8 to 30 points (a score of 8 points means that th person is independent; between 9 and 20 points means a moderate dependency; greater than 20 points means severe dependency).

    Measure: Change in functional status is assessed using the Lawton and Brody Instrumental Activities of Daily Living.

    Time: 12 months after the beginning of the intervention

    Other Outcomes

    Description: Sociodemographic data will be collected using a sociodemographic questionnaire, designed specifically for this study, regarding information about age, gender, literacy, health conditions, among others.

    Measure: Sociodemographic data collected through a sociodemographic questionnaire

    Time: Pre-intervention

    Description: Adherence to the intervention and dropouts will be assessed using a session form, designed specifically for this study, completed by the technician after each session, regarding the attendance and mood/behavior of the participants throughout the intervention sessions.

    Measure: Adherence to the intervention and dropouts evaluated through a session form

    Time: [Pre, intra (6 months) and post intervention (12 months)]
    7 A Randomized, Unblinded, 60-subject Three-wave Clinical Trial of an Occupational Therapy-led In-home Intervention Designed to Help Older Adults Successfully Transition to Their Homes Following a Skilled Nursing Facility Discharge

    This clinical study is designed to test the feasibility of a new intervention, CAPABLE Transitions. CAPABLE Transitions is based on the Community Aging in Place, Advancing Better Living for Elders (CAPABLE) intervention designed by Dr. Sarah Szanton at Johns Hopkins University. Similar to CAPABLE, CAPABLE Transitions consists of an occupational therapy (OT)-led intervention in which the study OT, nurse, and handyman deliver an in-home intervention over 3-4 months. This intervention is designed to help with the transition of care from the skilled nursing facility to home as well as to optimize functioning and home safety. This clinical study plans to recruit a total of 60 older adults with and without dementia admitted to a home health agency following discharge from a skilled nursing facility. Given that this is a feasibility study, it is not designed or powered to test hypotheses.

    NCT04460742
    Conditions
    1. Care Transitions
    2. Dementia
    Interventions
    1. Behavioral: CAPABLE Transitions
    2. Behavioral: Home Health Agency Care
    MeSH:Dementia
    HPO:Dementia

    Primary Outcomes

    Description: The study will monitor how many older adults are screened and satisfy the eligibility criteria.

    Measure: Proportion of participants screened as eligible

    Time: Through study completion, an average of 3 years

    Description: The study will monitor how many older adults who satisfy the eligibility criteria are enrolled in the study.

    Measure: Proportion of screened participants that enroll

    Time: Through study completion, an average of 3 years

    Description: The study will monitor the proportion of participants that complete the study.

    Measure: Proportion of enrolled participants that are retained

    Time: 6 months

    Description: Participants and study partners will be asked Likert-item response survey questions to assess the perceived benefit and burdensomeness of the intervention.

    Measure: Proportion of participants who perceive a benefit from the intervention

    Time: 3 months

    Description: Participants and study partners will be asked Likert-item response survey questions to assess the perceived benefit and burdensomeness of the intervention.

    Measure: Proportion of participants who perceive a benefit from the intervention

    Time: 6 months

    Description: The study will review audio recordings and study interventionists' documentation to examine fidelity to the intervention and score whether the interventionists completed the central tasks of CAPABLE Transitions. The study will score completion of the critical components as "yes" or "no" and this outcome will be reported as the proportion of critical components of the CAPABLE Transitions intervention that were completed by the occupational therapist and registered nurse.

    Measure: Proportion of Critical Tasks Completed

    Time: Throughout Study Intervention, an average of 5 months

    Description: The study will monitor the proportion of participants who have complete information on home time, quality of life, and health services utilization at 3 months.

    Measure: Data Completeness on Clinical Outcomes

    Time: 3 months

    Description: The study will monitor the proportion of participants who have complete information on home time, quality of life, and health services utilization at 6 months.

    Measure: Data Completeness on Clinical Outcomes

    Time: 6 months

    Secondary Outcomes

    Description: Home time is the number of days participants spend alive in non-institutional settings (e.g., nursing homes and hospitals). The study will report the participants' home time at 3 months of follow-up.

    Measure: Home Time in Days

    Time: 3 months

    Description: Home time is the number of days participants spend alive in non-institutional settings (e.g., nursing homes and hospitals). The study will report the participants' home time at 6 months of follow-up.

    Measure: Home Time in Days

    Time: 6 months

    Description: The study will examine quality of life (EQ-5D-5L) among study participants at 3 months of follow-up. Rating: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, each with 1 as lowest score and 5 as highest score: no problems, slight problems, moderate problems, severe problems and extreme problems, where higher scores indicate worse outcome. The EQ VAS question records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine' out of 100. Therefore higher scores may indicate better outcomes.

    Measure: Mean change in quality of life using EQ-5D-5L (unabbreviated title)

    Time: 3 months

    Description: The study will examine quality of life (EQ-5D-5L) among study participants at 6 months of follow-up. Rating: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, each with 1 as lowest score and 5 as highest score: no problems, slight problems, moderate problems, severe problems and extreme problems, where higher scores indicate worse outcome. The EQ VAS question records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine' out of 100. Therefore higher scores may indicate better outcomes.

    Measure: Mean change in quality of life using EQ-5D-5L (unabbreviated title)

    Time: 6 months

    Description: The study will examine the proportion of participants who went to the emergency department, were hospitalized, and were admitted to a skilled nursing facility within 3 months of follow-up. The study also will tabulate the mean number of times they used these services within 3 months of follow-up.

    Measure: Health Services Use

    Time: 3 Months

    Description: The study will examine the proportion of participants who went to the emergency department, were hospitalized, and were admitted to a skilled nursing facility within 6 months of follow-up. The study also will tabulate the mean number of times they used these services within 6 months of follow-up.

    Measure: Health Services Use

    Time: 6 Months
    8 Evidence-Based Supported Digital Intervention for Improving Wellbeing and Health of People Living in Care Homes and Care Home Staff (WHELD) During COVID-19: An RCT to Evaluate COVID-19 Adapted E-WHELD: Benefits and Cost-Effectiveness

    More than 400,000 people in the UK live in care homes. These individuals are particularly vulnerable to COVID-19; many are frail and the majority have concurrent physical health problems and dementia. This group are at the highest risk of becoming severely ill with COVID-19 and are dependent on a stretched care workforce. The isolation, together with the stresses and distressing nature of the current work environment is also likely to have an impact on the mental health and well-being of care staff. It is vital to provide good quality support to enable care staff to remain resilient, and to enable good quality care that maintains the well-being of residents with dementia and reduces emerging neuropsychiatric symptoms in residents without increasing harmful sedative medications. COVID E-WHELD is based on the optimized WHELD training intervention on successfully completed in randomised clinical trials (RCTs) in 86 care homes, more than 1000 people with dementia. WHELD reduced use of anti-psychotics, improved agitation and overall neuropsychiatric symptoms, improved quality of life and reduced mortality for people with dementia. A digital version of WHELD (eWHELD) with virtual supervision in a further care home RCT including 130 people with dementia has demonstrated benefits for staff carers and improvements in the quality of life of people with dementia, with eWHELD combined with virtual supervision, but not with e-learning alone. The current project will evaluate a COVID-19 adapted version of eWHELD to address current needs of care homes during the COVID-19 pandemic. This will be undertaken in a 2 arm, 4 month, randomized cluster RCT in 1280 care homes (allowing for 75% drop out with COVID-19 outbreaks) to determine whether COVID-19 adapted eWHELD improves quality of life and mental health for people with dementia in care homes and the mental health of care staff.

    NCT04590469
    Conditions
    1. Dementia
    Interventions
    1. Other: COVID WHELD
    MeSH:Dementia
    HPO:Dementia

    Primary Outcomes

    Description: Validated quality of life measure for people with dementia, assessed by informant interview. Minimum score = 32 Maximum score = 128; Higher score denotes better outcome.

    Measure: Dementia Quality of Life - DEMQOL proxy

    Time: 4 months

    Secondary Outcomes

    Description: Standardized assessment of neuropsychiatric symptoms in people with dementia, assessed by informant interview. Minimum score = 0 Maximum score = 144; Higher score denotes worse outcome.

    Measure: Neuropsychiatric Inventory

    Time: 4 months

    Description: Use of antipsychotic and other psychotropic medications from prescribing charts

    Measure: Psychotropic medications

    Time: 4 months

    Description: Staff confidence measure, self completed questionnaire. Minimum score = 9 Maximum score = 45; Higher score denotes better outcome.

    Measure: Confidence in Dementia (CODE) Scale

    Time: 4 months

    Description: Perceived self efficacy of care staff, self completed questionnaire. Minimum score = 17 Maximum score = 68; Higher score denotes better outcome.

    Measure: Sense of Competence in Dementia Care Staff (SCIDS) scale

    Time: 4 months

    Description: Mental Health of care staff, self reported questionnaire. Minimum score = 0 Maximum score = 27; Higher score denotes worse outcome.

    Measure: Patient Health Questionnaire (PHQ-9)

    Time: 4 months

    Description: A standardized instrument for measuring generic health related quality of life, used for Health economic evaluation. Visual Analogue scale minimum score = 0, maximum score = 100. Higher score denotes better outcome.

    Measure: EQ5D (Euroquol 5D - 5 dimensions)

    Time: 4 months

    Description: to collect service utilization data for health economics. Assesses cost of service provision; as such no min/max values. Higher value denotes worse cost outcome.

    Measure: Client Service Receipt Inventory

    Time: 4 months

    Other Outcomes

    Description: Ordinal scale to rate progress towards personalized goals for people with dementia as a process outcome. Scale for each goal: Minimum score = 1 Maximum score = 4; Higher score denotes better outcome.

    Measure: Goal Attainment Scaling

    Time: 4 months

    HPO Nodes


    HP:0000726: Dementia
    Genes 291
    PRNP PRDM8 VCP TRNL1 GIGYF2 GRN IRF6 SNCB C9ORF72 DNAJC13 PNPLA6 MAPT APP PDGFRB PSEN2 ATP13A2 PRNP TREM2 FTL HFE PINK1 SNCA PPP2R2B GBA2 PRNP TYMP SNCA HTT MAPT MAPT PRNP GLUD2 TTR PSEN1 TRPM7 TRNE C19ORF12 GBA NPC1 ATP6V0A2 PSEN1 ATXN2 PANK2 WFS1 C9ORF72 CSTB COX3 CYTB ZFYVE26 ROGDI DNMT1 PRKN NDP FUS SNCA ADH1C LRRK2 AUH SYNJ1 TBK1 MAPT DNAJC6 SNCA SERPINI1 HNRNPA1 SDHD VPS13C GCDH GBA APP CHCHD10 ATP6 C9ORF72 TRNQ TRNQ DCTN1 COX2 SPG21 SDHA CUBN PDGFB TBP NHLRC1 PODXL PINK1 TRNF ATP13A2 WDR45 VCP CHMP2B NOTCH2NLC TOMM40 C9ORF72 JPH3 EPM2A CSF1R CHMP2B VCP ARSA NPC2 TIMM8A TREX1 TRNH MATR3 JPH3 CHMP2B LYST LRRK2 GRN MPO PRNP EPM2A APP VCP TREM2 PPP2R2B TMEM106B COX3 ALDH18A1 ND1 ADA2 PRNP CLN6 MATR3 ATP13A2 CST3 VPS13C ATP6V1A TMEM106B SQSTM1 SNCA ND1 VPS35 MECP2 ABCD1 DNAJC5 TREM2 EIF4G1 SLC13A5 ATP6V1E1 PRNP ATXN2 GBA GRN FMR1 COL4A1 HLA-DQB1 TRNW SCARB2 GRN PSEN1 TRNS2 TYROBP TREM2 PSEN1 SDHAF1 ATN1 RNF216 CHMP2B APOE TRNS2 TRNS1 NOTCH3 HTT COX2 XPR1 TWNK GM2A ROGDI ERCC4 NR4A2 RNF216 SNCA PSAP GBA TRNK ATXN10 APP PRKAR1B OPA1 KCTD7 MAPT PRICKLE1 DGUOK APP TRNV GBA2 ITM2B WFS1 TARDBP ND4 POLG APP TUBA4A TARDBP ND5 LRRK2 SPG21 PANK2 PSEN2 CP COX1 SORL1 UBQLN2 CYP27A1 ND6 TREM2 HEXA PRDX1 MAPT A2M PLA2G6 SQSTM1 MBTPS2 ATP6 APP MMACHC VCP SPAST CERS1 RAB39B VPS13A ATN1 ALDH18A1 HNRNPA2B1 TBK1 TYROBP SQSTM1 HTRA1 AARS2 ATXN3 CLN3 CTSF ATXN2 MAPT TRNW CHMP2B TRNC DCTN1 HNRNPA2B1 RRM2B TBP NOTCH3 ASAH1 DNMT1 ND6 WDR45 ATXN8OS CFAP43 ITM2B TRNF FMR1 GBE1 MAPT APTX FTL VCP C9ORF72 PLA2G6 ND5 NHLRC1 DNM1L ERCC8 UCHL1 TUBB4A TREM2 CISD2 PSEN1 POLG MAPT PSEN1 PLAU FBXO7 HTRA1 ATP13A2 NOTCH2NLC APOE ABCA7 PSEN1 NOS3 CHCHD10 SNCAIP TRNL1 ATP7B COX1 PARK7 TMEM106B HTRA2 TRNS1 GBA SDHB
    Protein Mutations 1
    V158M
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0000726: Dementia
    Genes 291
    PRNP PRDM8 VCP TRNL1 GIGYF2 GRN IRF6 SNCB C9ORF72 DNAJC13 PNPLA6 MAPT APP PDGFRB PSEN2 ATP13A2 PRNP TREM2 FTL HFE PINK1 SNCA PPP2R2B GBA2 PRNP TYMP SNCA HTT MAPT MAPT PRNP GLUD2 TTR PSEN1 TRPM7 TRNE C19ORF12 GBA NPC1 ATP6V0A2 PSEN1 ATXN2 PANK2 WFS1 C9ORF72 CSTB COX3 CYTB ZFYVE26 ROGDI DNMT1 PRKN NDP FUS SNCA ADH1C LRRK2 AUH SYNJ1 TBK1 MAPT DNAJC6 SNCA SERPINI1 HNRNPA1 SDHD VPS13C GCDH GBA APP CHCHD10 ATP6 C9ORF72 TRNQ TRNQ DCTN1 COX2 SPG21 SDHA CUBN PDGFB TBP NHLRC1 PODXL PINK1 TRNF ATP13A2 WDR45 VCP CHMP2B NOTCH2NLC TOMM40 C9ORF72 JPH3 EPM2A CSF1R CHMP2B VCP ARSA NPC2 TIMM8A TREX1 TRNH MATR3 JPH3 CHMP2B LYST LRRK2 GRN MPO PRNP EPM2A APP VCP TREM2 PPP2R2B TMEM106B COX3 ALDH18A1 ND1 ADA2 PRNP CLN6 MATR3 ATP13A2 CST3 VPS13C ATP6V1A TMEM106B SQSTM1 SNCA ND1 VPS35 MECP2 ABCD1 DNAJC5 TREM2 EIF4G1 SLC13A5 ATP6V1E1 PRNP ATXN2 GBA GRN FMR1 COL4A1 HLA-DQB1 TRNW SCARB2 GRN PSEN1 TRNS2 TYROBP TREM2 PSEN1 SDHAF1 ATN1 RNF216 CHMP2B APOE TRNS2 TRNS1 NOTCH3 HTT COX2 XPR1 TWNK GM2A ROGDI ERCC4 NR4A2 RNF216 SNCA PSAP GBA TRNK ATXN10 APP PRKAR1B OPA1 KCTD7 MAPT PRICKLE1 DGUOK APP TRNV GBA2 ITM2B WFS1 TARDBP ND4 POLG APP TUBA4A TARDBP ND5 LRRK2 SPG21 PANK2 PSEN2 CP COX1 SORL1 UBQLN2 CYP27A1 ND6 TREM2 HEXA PRDX1 MAPT A2M PLA2G6 SQSTM1 MBTPS2 ATP6 APP MMACHC VCP SPAST CERS1 RAB39B VPS13A ATN1 ALDH18A1 HNRNPA2B1 TBK1 TYROBP SQSTM1 HTRA1 AARS2 ATXN3 CLN3 CTSF ATXN2 MAPT TRNW CHMP2B TRNC DCTN1 HNRNPA2B1 RRM2B TBP NOTCH3 ASAH1 DNMT1 ND6 WDR45 ATXN8OS CFAP43 ITM2B TRNF FMR1 GBE1 MAPT APTX FTL VCP C9ORF72 PLA2G6 ND5 NHLRC1 DNM1L ERCC8 UCHL1 TUBB4A TREM2 CISD2 PSEN1 POLG MAPT PSEN1 PLAU FBXO7 HTRA1 ATP13A2 NOTCH2NLC APOE ABCA7 PSEN1 NOS3 CHCHD10 SNCAIP TRNL1 ATP7B COX1 PARK7 TMEM106B HTRA2 TRNS1 GBA SDHB
    Protein Mutations 1
    V158M
    SNP 0

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook